|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00034957 |
Purpose
The primary goal of the study is to evaluate an investigational drug's effectiveness as a treatment for Non small-cell lung cancer (NSCLC)
| Condition | Intervention | Phase |
|
Carcinoma, Non-Small-Cell Lung Lung Neoplasms |
Drug: Investigational drug |
Phase II |
| MedlinePlus related topics: | Cancer Lung Cancer |
| Study Type: | Interventional |
| Study Design: | Treatment |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Inclusion Criteria: Eligible patients must be at least 18 years of age with a diagnosis of NSCLC that has gotten worse during or after treatment with platinum-based chemotherapy. Patients must have at least one tumor that can be evaluated by the doctor during the investigational drug treatment. Any side-effects from prior chemotherapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function.
Exclusion Criteria: Any of the following will exclude patients from study participation: receipt of more than 1 prior regimen of chemotherapy for NSCLC (repeat of the same chemotherapy at different points in time count as 1 regimen). Irradiation to 25% or more of bone marrow, prior high dose chemotherapy with bone marrow or stem cell support, current participation in other clinical trials, pregnant or breast-feeding women, known HIV-positive or AIDS-related illness.
Contacts and Locations| United States, California | |||||
| Research Center | |||||
| Greenbrae, California, United States, 94904-2007 | |||||
| Research Center | |||||
| Berkeley, California, United States, 94704 | |||||
| Research Center | |||||
| Rancho Mirage, California, United States, 92270 | |||||
| Research Center | |||||
| Los Angeles, California, United States, 90048 | |||||
| United States, Illinois | |||||
| Research Center | |||||
| Chicago, Illinois, United States, 60637-1463 | |||||
| United States, Kentucky | |||||
| Research Center | |||||
| Louisville, Kentucky, United States, 40202 | |||||
| United States, Massachusetts | |||||
| Research Center | |||||
| West Boylston, Massachusetts, United States, 01583 | |||||
| United States, Michigan | |||||
| Research Center | |||||
| Ann Arbor, Michigan, United States, 48109 | |||||
| United States, New Hampshire | |||||
| Research Center | |||||
| Lebanon, New Hampshire, United States, 03756 | |||||
| United States, Tennessee | |||||
| Research Center | |||||
| Nashville, Tennessee, United States, 37232-6868 | |||||
| United States, Texas | |||||
| Research Center | |||||
| Arlington, Texas, United States, 76012 | |||||
| Research Center | |||||
| Dallas, Texas, United States, 75390 | |||||
| Pfizer |
More Information
| Study ID Numbers: | 196-ONC-0100-005 |
| First Received: | May 2, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00034957 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|